Abstract
Introduction: Intracranial hemorrhagic disease can present with transient focal neurological symptoms. Congenital fibrinogen diseases are unusual and can rarely manifest in this way. Below we present a case of cerebral microbleeds due to congenital hypofibrinogenemia with transient focal neurological symptoms.
Case presentation: This is a 29-year-old man with cerebral microbleeds due to congenital hypofibrinogenemia with transient focal neurological symptoms.
Discussion: Cerebral microbleed and intracerebral hemorrhage is a cause of transient focal neurological symptoms. The prevalence of cerebral microbleeds in the elderly population is a highly recognized problem. However, the incidence of these microbleeds in younger people is low and unknown. Blood dyscrasias, such as inherited fibrinogen disorder, are a cause of inherited abnormalities of blood clotting. Fibrinogen has an important role in the control of bleeding due to platelet aggregation and is part of the coagulation cascade. The absence of normal fibrinogen induces alteration in platelet and coagolation hemostasis and, therefore, causes hemorrhagic complications.
Conclusions: Transient focal neurological symptoms may be caused by small vessel hemorrhagic cerebrovascular disease. Congenital blood dyscrasias are a rare cause of this type of cerebrovascular disease.
References
Arauz A, Ruíz-Franco A. Enfermedad vascular cerebral. Rev Fac Med. 2012;55(3):11-21.
Siket MS, Edlow J. Transient ischemic attack: an evidence-based update. Emerg Med Pract. 2013 en.;15(1):1-26.
Yood RA, Skinner M, Rubinow A, Talarico L, Cohen AS. Bleeding manifestations in 100 patients with amyloidosis. JAMA. 1983;249(10):1322-4. https://doi.org/10.1001/jama.249.10.1322
Zubkov AY, Rabinstein AA, Dispenzieri A, Wijdicks EF. Primary systemic amyloidosis with ischemic stroke as a presenting complication. Neurology. 2007 sept. 11;69(11):1136-41. https://doi.org/10.1212/01.wnl.0000276951.39112.2b
Sucker C, Hetzel GR, Grabensee B, Stockschlaeder M, Scharf RE. Amyloidosis and bleeding: pathophysiology, diagnosis, and therapy. Am J Kidney Dis. 2006 jun. 1;47(6):947-55. https://doi.org/10.1053/j.ajkd.2006.03.036
Caplan LR. Transient ischemic attack: definition and natural history. Curr Atheroscleros Rep. 2006 jul.;8(4):276-80. https://doi.org/10.1007/s11883-006-0004-1
Vermeer SE, Longstreth Jr WT, Koudstaal PJ. Silent brain infarcts: a systematic review. Lancet Neurol. 2007 jul. 1;6(7):611-9. https://doi.org/10.1016/S1474-4422(07)70170-9
Ramírez-Moreno JM, Gaspar-García E, Gómez-Baquero MJ. Microsangrados cerebrales múltiples en paciente con hipertensión mal controlada. Un nuevo marcador de vasculopatía hipertensiva. Hipertensión Riesgo Vascular. 2011 my. 1;28(3):108-11. https://doi.org/10.1016/j.hipert.2010.11.001
Tapia J. Hemorragia encefálica por angiopatía amiloidea. Rev Méd Chile. 2021 en. 1;149(1):76-87. https://doi.org/10.4067/S0034-98872021000100076
Campbell-Silva S, Gómez-Pinedo RA, Ramírez-Blanco LA. Síndrome de vasoconstricción cerebral reversible. Acta Méd Colomb. 2019 sept. 15;44(3).
Haller S, Vernooij MW, Kuijer JP, Larsson EM, Jäger HR, Barkhof F. Cerebral microbleeds: imaging and clinical significance. Radiology. 2018;287(1):11-28.
Brotons C. Los pacientes que presentan un ataque neurológico transitorio sin déficit neurológico focal o mixto (síntomas focales y no focales) tienen un mayor riesgo de enfermedad vascular y demencia. FMC. 2008 ag. 1;15(7):481. https://doi.org/10.1016/S1134-2072(08)72239-4
Hillis AE, Wityk RJ, Barker PB, Beauchamp NJ, Gailloud P, Murphy K, et al. Subcortical aphasia and neglect in acute stroke: the role of cortical hypoperfusion. Brain. 2002 my. 1;125(5):1094-104. https://doi.org/10.1093/brain/awf113
Martinez-Ramirez S, Greenberg SM, Viswanathan A. Cerebral microbleeds: overview and implications in cognitive impairment. Alzheimers Res Ther. 2014 jun.;6(3):1-7. https://doi.org/10.1186/alzrt263
Vargas-Ruiz ÁG. El fibrinógeno: su fisiología e interacciones en el sistema de la coagulación. Rev Mex Anestesiol. 2016 jun. 23;39(S2):321-3.
De Moerloose P, Neerman-Arbez M. Congenital fibrinogen disorders. Semin Thromb Hemost. 2009;35(04):356-66. https://doi.org/10.1055/s-0029-1225758
Medved L, Weisel JW. Recommendations for nomenclature on fibrinogen and fibrin. J Thromb Haemost. 2009 febr.;7(2):355. https://doi.org/10.1111/j.1538-7836.2008.03242.x
Asselta R, Paraboschi EM, Duga S. Hereditary hypofibrinogenemia with hepatic storage. Int J Mol Sci. 2020;21(21):7830. https://doi.org/10.3390/ijms21217830
Brunclikova M, Simurda T, Zolkova J, Sterankova M, Skornova I, Dobrotova M, et al. Heterogeneity of genotype-phenotype in congenital hypofibrinogenemia-a review of case reports associated with bleeding and thrombosis. J Clin Med. 2022;11(4):1083. https://doi.org/10.3390/jcm11041083
Luo M, Xiang L, Yan J, Liao L, Wu Y, Deng X, et al. Fibrinogen clauss and prothrombin time derived method ratio can differentiate dysfibrinogenemia from hypofibrinogenemia and hyperfibrinogenemia. Thromb Res. 2020;194:197-9. https://doi.org/10.1016/j.thromres.2020.07.023
Martin AC, Samama CM. Medicamentos derivados del plasma: fracciones coagulantes y anticoagulantes. EMC-Anestesia-Reanimación. 2014 nov. 1;40(4):1-3. https://doi.org/10.1016/S1280-4703(14)68947-7
Lissitchkov T, Madan B, Djambas Khayat C, Zozulya N, Ross C, Karimi M, et al. Fibrinogen concentrate for treatment of bleeding and surgical prophylaxis in congenital fibrinogen deficiency patients. J Thromb Haemost. 2020 abr.;18(4):815-24. https://doi.org/10.1111/jth.14727
Tziomalos K, Vakalopoulou S, Perifanis V, Garipidou V. Treatment of congenital fibrinogen deficiency: overview and recent findings. Vasc Health Risk Manag. 2009;5:843. https://doi.org/10.2147%2Fvhrm.s5305
Peyvandi F. Epidemiology and treatment of congenital fibrinogen deficiency. Thromb Res. 2012;130(supl. 2):S7-S11. https://doi.org/10.1016/S0049-3848(13)70004-5
Idris SF, Hadjinicolaou AV, Sweeney M, Winthrop C, Balendran G, Besser M. The efficacy and safety of cryoprecipitate in the treatment of acquired hypofibrinogenaemia. Br J Haematol. 2014 ag.;166(3):458-61. https://doi.org/10.1111/bjh.12864
de Moerloose P, Neerman-Arbez M. Treatment of congenital fibrinogen disorders. Expert Opin Biol Ther. 2008 jul. 1;8(7):979-92. https://doi.org/10.1517/14712598.8.7.979
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.